Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-307 as an Adjunctive Treatment in Relapsing-Remitting Multiple Sclerosis
NCT06083753Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PIPE-307 in relapsing-remitting multiple sclerosis (RRMS), sponsored by Janssen Pharmaceutical. Started Nov 2023; status: completed.
02
Drugs
PIPE-307
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06083753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083753.